Lucilla Parnetti
#151,254
Most Influential Person Now
Researcher
Lucilla Parnetti's AcademicInfluence.com Rankings
Lucilla Parnettibiology Degrees
Biology
#11330
World Rank
#14718
Historical Rank
Biotechnology
#187
World Rank
#189
Historical Rank
Physiology
#361
World Rank
#578
Historical Rank
Genetics
#1221
World Rank
#1322
Historical Rank
Download Badge
Biology
Lucilla Parnetti's Degrees
- Masters Biology University of Florence
- Bachelors Biotechnology University of Milan
Similar Degrees You Can Earn
Why Is Lucilla Parnetti Influential?
(Suggest an Edit or Addition)Lucilla Parnetti's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009) (1139)
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
- Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain Infarction (2003) (534)
- Neurofilament light chain as a biomarker in neurological disorders (2019) (425)
- The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
- A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine–acetylcholine synaptic balance (2006) (320)
- A Practical Guide to Immunoassay Method Validation (2015) (320)
- Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative (2012) (295)
- Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. (2012) (291)
- CSF and blood biomarkers for Parkinson's disease (2019) (263)
- The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? (2014) (258)
- Dysphagia following Stroke (2004) (249)
- New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) (246)
- Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease (2014) (214)
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
- Consensus guidelines for lumbar puncture in patients with neurological diseases (2017) (197)
- Cerebrospinal fluid biomarkers in Parkinson disease (2013) (192)
- Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease (2017) (180)
- A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease (2009) (179)
- The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative (2014) (174)
- Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies (2008) (164)
- Age and diagnostic performance of Alzheimer disease CSF biomarkers (2012) (163)
- Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease (2006) (159)
- Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias (2011) (157)
- Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies (2006) (151)
- Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease (2016) (148)
- CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies (2001) (143)
- Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis (2017) (141)
- Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases (2015) (140)
- Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease (2014) (135)
- Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging (1997) (133)
- A multicentre validation study of the diagnostic value of plasma neurofilament light (2021) (130)
- Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory (2009) (129)
- Mild Hyperhomocyst(e)inemia: A Possible Risk Factor for Cervical Artery Dissection (2001) (124)
- Lysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links (2016) (121)
- Role of homocysteine in age-related vascular and non-vascular diseases (1997) (119)
- Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
- 1H‐MRS, MRI‐Based Hippocampal Volumetry, and 99mTc‐HMPAO‐SPECT in Normal Aging, Age‐Associated Memory Impairment, and Probable Alzheimer's Disease (1996) (116)
- Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients (2017) (115)
- Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression (2016) (113)
- Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies (2015) (112)
- Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease (2007) (109)
- Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. (2004) (107)
- Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers (2006) (104)
- Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? (2001) (102)
- Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data (2001) (98)
- Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease (2018) (98)
- Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? (2007) (96)
- Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies (2015) (96)
- FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort (2018) (95)
- A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation (2018) (95)
- Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia (2017) (94)
- Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. (2012) (91)
- Acute Phase Reactant α1Antichymotrypsin Is Increased in Cerebrospinal Fluid and Serum of Patients with Probable Alzheimer Disease (1995) (87)
- Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2021) (85)
- Pattern of Tau forms in CSF is altered in progressive supranuclear palsy (2009) (84)
- Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS (2012) (82)
- Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease (2013) (82)
- Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study (2016) (79)
- Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies (2018) (77)
- White Matter Changes in Stroke Patients (1999) (75)
- Activation of the Contact System in Cerebrospinal Fluid of Patients with Alzheimer Disease (1998) (75)
- The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. (2016) (75)
- Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke (2004) (74)
- Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study (2019) (72)
- Levetiracetam monotherapy in Alzheimer patients with late‐onset seizures: a prospective observational study (2007) (70)
- Blood‐brain‐barrier in a geriatric population: barrier function in degenerative and vascular dementias (1991) (70)
- Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia (1995) (68)
- Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors (2002) (68)
- Idebenone in senile dementia of Alzheimer type: a multicentre study. (1992) (67)
- Atrial fibrillation in patients with first‐ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome (2005) (66)
- Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimer’s Disease (1996) (66)
- Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’ (2016) (65)
- Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia (2015) (65)
- Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type (2004) (65)
- New insights on the genetic etiology of Alzheimer’s and related dementia (2020) (64)
- Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies (2009) (63)
- Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis (2019) (63)
- Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study (2008) (63)
- Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology (2006) (63)
- The Vicious Cycle Between α‐Synuclein Aggregation and Autophagic‐Lysosomal Dysfunction (2019) (61)
- Free water elimination improves test–retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects (2017) (61)
- Recanalization of Cervical Artery Dissection: Influencing Factors and Role in Neurological Outcome (2003) (59)
- Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders (2016) (58)
- Cognitive enhancement therapy for Alzheimer's disease. The way forward. (1997) (57)
- Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI) (2017) (57)
- Neurovascular territory involved in different etiological subtypes of ischemic stroke in the Perugia Stroke Registry (2003) (56)
- Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology (2019) (55)
- CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. (2011) (55)
- Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort (2018) (54)
- Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease (2003) (54)
- Early admission to stroke unit influences clinical outcome (2006) (53)
- Activation of complement and contact system in Alzheimer's disease (2001) (52)
- Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of “Protein-Misfolding Cyclic Amplification” and “Real-Time Quaking-Induced Conversion” as Diagnostic Tools (2018) (52)
- Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease (2019) (52)
- Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? (1999) (51)
- Vascular dementia: the role of cerebral infarcts. (1999) (51)
- Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link? (2016) (51)
- Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: a study in an Italian population with dementia (2001) (50)
- Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy (2008) (50)
- Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis. (2016) (49)
- Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease Patients (2012) (47)
- Increased cerebrospinal fluid pyruvate levels in Alzheimer's disease (1995) (47)
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
- Guidelines for the diagnosis of dementia and Alzheimer's disease (2000) (43)
- Acetyl-L-carnitine in the treatment of mildly demented elderly patients. (1990) (43)
- Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice (2016) (43)
- THE PERUGIA HOSPITAL-BASED STROKE REGISTRY: REPORT OF THE 2ND YEAR (2002) (43)
- Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease (2017) (43)
- Pharmacological treatment of non-cognitive disturbances in dementia disorders (2001) (43)
- Radioligand binding assay of M1–M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes (1999) (42)
- Clinical Pharmacokinetics of Drugs for Alzheimer’s Disease (1995) (42)
- Is Ultrasound Examination Sufficient in the Evaluation of Patients with Internal Carotid Artery Severe Stenosis or Occlusion? (2003) (41)
- Multicentre Study of l-α-Glyceryl-Phosphorylcholine vs ST200 among Patients with Probable Senile Dementia of Alzheimer’s Type (1993) (41)
- Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina (2001) (40)
- Monoamine Metabolites in Cerebrospinal Fluid and Behavioral Ratings in Patients with Early and Late Onset of Alzheimer Dementia (1989) (39)
- Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study (1991) (38)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (38)
- Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease (2019) (37)
- Test‐retest reliability of the default mode network in a multi‐centric fMRI study of healthy elderly: Effects of data‐driven physiological noise correction techniques (2016) (36)
- Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders (1994) (36)
- Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats (2006) (36)
- GENETICS OF ISCHEMIC STROKE (2002) (35)
- Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. (2016) (35)
- The region 1–11 of Alzheimer amyloid-β is critical for activation of contact-kinin system (2001) (35)
- CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. (2020) (35)
- Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly (2015) (35)
- Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? (2008) (35)
- Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid (2007) (34)
- THE INFLAMMATORY RESPONSE IN CEREBRAL ISCHEMIA: FOCUS ON CYTOKINES IN STROKE PATIENTS (2002) (34)
- The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases (2015) (34)
- Changes in CSF acetyl‐ and butyrylcholinesterase activity after long‐term treatment with AChE inhibitors in Alzheimer’s disease (2011) (33)
- Secondary Prevention of Stroke in Patients with Atrial Fibrillation: Factors Influencing the Prescription of Oral Anticoagulation at Discharge (2006) (33)
- Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment (2016) (33)
- Differences in Extracellular Matrix Production and Basic Fibroblast Growth Factor Response in Skin Fibroblasts from Sporadic and Familial Alzheimer’s Disease (2007) (33)
- Parkinson's and Lewy body dementia CSF biomarkers. (2019) (33)
- Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis (2019) (33)
- A magnetization transfer study of mild and advanced Parkinson’s disease (2011) (33)
- Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study (2000) (32)
- Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study (2015) (32)
- Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group. (1993) (32)
- Cerebrospinal fluid pyruvate levels in Alzheimer’s disease and vascular dementia (2000) (31)
- Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia (2012) (31)
- Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide (2008) (31)
- Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting (2009) (31)
- Posatirelin for the treatment of late‐onset Alzheimer's disease: a double‐blind multicentre study vs citicoline and ascorbic acid (1995) (30)
- Monoamines and their metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type using high performance liquid chromatography and gas chromatography‐mass spectrometry (1987) (30)
- Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. (1997) (30)
- Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients (1997) (30)
- CSF‐Phospho‐tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies (2002) (29)
- Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. (2016) (29)
- Effect of MTHFR Polymorphisms on Hyperhomocysteinemia in Levodopa-treated Parkinsonian Patients (2007) (29)
- Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease (2020) (28)
- Amyloid-β: a potential link between epilepsy and cognitive decline (2021) (28)
- Posatirelin in the treatment of vascular dementia: a double‐blind multicentre study vs placebo (1996) (27)
- First-Ever Stroke and Outcome in Patients Admitted to Perugia Stroke Unit: Predictors for Death, Dependency, and Recurrence of Stroke within the First Three Months (2006) (27)
- Stroke Related to Carotid Artery Dissection in a Young Patient with Takayasu Arteritis, Systemic Lupus erythematosus and Antiphospholipid Antibody Syndrome (2002) (26)
- Associations of Alzheimer's disease with macular degeneration. (2017) (26)
- Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result (2018) (26)
- Vascular dementia: the role of cerebral infarcts (1999) (26)
- CSF Biomarkers Profile in CADASIL—A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder (2010) (26)
- Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study (2020) (25)
- A novel spinocerebellar ataxia type 15 family with involuntary movements and cognitive decline (2011) (25)
- Evidence of practice effect in CANTAB spatial working memory test in a cohort of patients with mild cognitive impairment (2018) (25)
- Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation (2015) (25)
- cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases (2010) (25)
- Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid (2014) (24)
- Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. (2006) (24)
- The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients (2019) (23)
- Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. (2019) (23)
- Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. (2016) (23)
- Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. (2021) (23)
- Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia (1993) (22)
- Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease (2017) (22)
- Is multi‐infarct dementia representative of vascular dementias? A retrospective study (1990) (22)
- Epidemiology of Vascular Dementia (1998) (22)
- Multicenter clinical placebo‐controlled study with acetyl‐l‐carnitine (LAC) in the treatment of mildly demented elderly patients (1988) (22)
- Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. (2019) (21)
- Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice (2003) (21)
- Fingerprinting Alzheimer's Disease by 1H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. (2020) (21)
- Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies (2018) (21)
- The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease. (2019) (21)
- Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases (2019) (21)
- CSF levels of β‐amyloid 1‐42, tau and phosphorylated tau protein in CADASIL (2008) (21)
- Immunological Profile of Silent Brain Infarction and Lacunar Stroke (2013) (21)
- Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers (2020) (20)
- Magnetization transfer MRI in dementia disorders, Huntington's disease and parkinsonism (2015) (20)
- Semi-quantitative analysis of perfusion of Brodmann areas in the differential diagnosis of cognitive impairment in Alzheimer's disease, fronto-temporal dementia and mild cognitive impairment. (2009) (20)
- Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: a marker of cholinergic dysfunction? (2001) (20)
- Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms (2019) (20)
- Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid (2021) (19)
- The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers (2020) (19)
- Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids. (2019) (19)
- Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias (1992) (19)
- Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. (2016) (19)
- Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis. (2019) (18)
- No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF (2016) (18)
- CSF monoamine metabolites in old age dementias. (1992) (18)
- Headache associated with acute ischemic stroke (2001) (18)
- Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study (2020) (18)
- Neuroendocrine markers in aging brain: Clinical and neurobiological significance of dexamethasone suppression test (1990) (18)
- Evolutionary Trends in Carotid Atherosclerotic Plaques: Results of a Two-Year Follow-up Study Using an Ultrasound Imaging System (1988) (18)
- Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. (2019) (17)
- Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics (2020) (17)
- Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study (2019) (17)
- Meal-induced arterial blood pressure variations in the elderly. (1988) (17)
- Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts. (2019) (17)
- The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie. (2016) (17)
- The role of haemorheological factors in the ageing brain: long-term therapy with pentoxifylline ('Trental' 400) in elderly patients with initial mental deterioration. (1986) (17)
- Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. (2019) (17)
- Platelet MAO-B activity and vitamin B12 in old age dementias. (1992) (17)
- Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifylline. (1985) (16)
- Arterial hypertension and cognitive dysfunction in physiologic and pathologic aging of the brain. (2007) (16)
- Characteristics of Delayed Admission to Stroke Unit (2006) (16)
- Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. (2019) (16)
- α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies (2022) (16)
- The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis (2021) (16)
- Pathogenetic mechanisms in vascular dementia (1994) (16)
- Time trends, frequency, characteristics and prognosis of short‐duration transient global amnesia (2020) (16)
- Arterial Hypertension and Stroke Prevention: An Update (2006) (16)
- Risk Factors and Stroke Subtypes: Results of Five Consecutive Years of the Perugia Stroke Registry (2006) (16)
- Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders? (2019) (15)
- Italian consensus recommendations for a biomarker‐based aetiological diagnosis in mild cognitive impairment patients (2020) (15)
- Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. (2022) (15)
- A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies (2020) (15)
- Cognitive Enhancement Therapy for Alzheimer’s Disease (1997) (15)
- A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy. (2010) (15)
- Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals (2019) (14)
- Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. (2011) (14)
- Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study (2018) (14)
- BRAIN CT-SCAN IN ACUTE STROKE PATIENTS: SILENT INFARCTS AND RELATION TO OUTCOME (2002) (14)
- Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia (2011) (14)
- Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers (2022) (14)
- Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain (2021) (14)
- Hippocampal epileptogenesis in autoimmune encephalitis (2019) (14)
- Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics (2021) (14)
- Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. (2020) (13)
- Clinical Experience with Aniracetam in the Treatment of Senile Dementia of the Alzheimer’s Type and Related Disorders (1993) (13)
- HEART–BRAIN RELATIONSHIP: ATRIAL FIBRILLATION AND STROKE (2002) (13)
- Vertebral Artery Dissection and Hyperhomocysteinemia: A Case Report (2000) (12)
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (12)
- Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study (2014) (12)
- T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson's disease (2019) (12)
- Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis (2021) (12)
- CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD (2019) (12)
- The Italian version of cognitive function instrument (CFI): reliability and validity in a cohort of healthy elderly (2017) (12)
- The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design (2016) (12)
- Spatial cognition in Parkinson’s disease and neurodegenerative dementias (2006) (11)
- Multicentre Controlled Randomised Double-Blind Placebo Study of Minaprine in Elderly Patients Suffering from Prolonged Depressive Reaction (1993) (11)
- Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type (2006) (11)
- The Mental Deterioration Battery (Part 1): Description of a instrument of the neuropsychological diagnosis (1995) (11)
- Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. (2020) (11)
- Diagnostic value of plasma neurofilament light: A multicentre validation study (2020) (11)
- Dual Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke: A Ghost from the Past or a New Frontier? (2010) (10)
- Clinical and genetic analysis of hereditary and sporadic ataxia in central Italy (2001) (10)
- Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group. (1989) (10)
- Selection of thrombogenetic antiphospholipid antibodies in cerebrovascular disease patients (2003) (10)
- Levodopa treatment in Parkinson's disease: earlier or later? (2019) (10)
- Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. (2017) (10)
- Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis (2016) (10)
- Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
- Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No? (2017) (10)
- CSF cutoffs for MCI due to AD depend on APOEε4 carrier status (2019) (9)
- HYPERHOMOCYST(E)INEMIA: A RISK FACTOR FOR CEREBROVASCULAR DISEASE (2002) (9)
- Early manifestations of dementing illness: Treatment with glycosaminoglycan polysulfate (1992) (9)
- Early detection of dementia in clinical practice (2006) (9)
- Role of Neuroprotective Drugs inAcute Ischemic Stroke (2000) (9)
- Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies (2021) (9)
- Prestroke dementia in patients with atrial fibrillation. Frequency and associated factors. (2005) (9)
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (9)
- Prestroke dementia in patients with atrial fibrillation (2005) (8)
- Stroke Prevention and Statin Treatment (2006) (8)
- Efficacy of Thrombolytic (rt-PA) Therapy in Old Stroke Patients: The Perugia Stroke Unit Experience (2006) (8)
- Association Between Migraine and Headache Attributed to Stroke: A Case–Control Study (2008) (8)
- Therapeutic options in dementia (2000) (8)
- Effect of Acetyl-L-Carnitine on Serum Levels of Cortisol and Adrenocorticotropic Hormone and Its Clinical Effect in Patients with Senile Dementia of Alzheimer Type (1990) (8)
- Memory impairment in the elderly: a three-year follow-up. (1985) (8)
- INCREASED CSF PYRUVATE LEVELS AS A MARKER OF IMPAIRED ENERGY METABOLISM IN ALZHEIMER'S DISEASE (1995) (8)
- Glycosaminoglycan polysulfate in primary degenerative dementia. Pilot study of biologic and clinical effects. (1995) (8)
- High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer’s disease (2021) (8)
- Diagnosing Alzheimer's disease in very elderly patients. Relevance of some functional and psychobehavioral aspects assessed by the Gottfries-Bråne-Steen Rating Scale for Dementia. Study Group on Brain Aging, Italian Society of Gerontology and Geriatrics. (1997) (7)
- Educational Approach on Stroke Training in Europe (2006) (7)
- Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. (2019) (7)
- Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction (2021) (7)
- Origin of α-mannosidase activity in CSF. (2017) (7)
- Cerebrospinal Fluid b-Glucocerebrosidase Activity Is Reduced in Parkinson ’ s Disease Patients (2017) (7)
- Aniracetam (Ro 13-5057) for the Treatment of Senile Dementia of Alzheimer Type: Results of a Multicentre Clinical Study (1991) (7)
- Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms (2020) (6)
- Extracranial Carotid Atherosclerosis Evaluation and Stroke Occurrence: Role of the Echotomographic Analysis (1988) (6)
- Novel noninvasive biomarkers of prodromal Alzheimer disease: The role of optical coherence tomography and optical coherence tomography–angiography (2021) (6)
- Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study (2015) (6)
- The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up (2019) (6)
- Multimodal Use of Computed Tomography in Early Acute Stroke, Part 2 (2006) (6)
- Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis (2016) (6)
- Biochemical diagnosis of neurodegenerative diseases gets closer (2011) (6)
- Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. (2016) (6)
- Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease (2012) (6)
- Hemorheologic Factors in the Postacute Phase of Ischemic Stroke (1988) (6)
- Changes of olfactory tract in Parkinson’s disease: a DTI tractography study (2020) (6)
- Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis (2017) (6)
- Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment. (2018) (6)
- Estimating the inheritance of frontotemporal lobar degeneration in the Italian population. (2014) (6)
- Pathophysiology of vascular dementia and white matter changes. (1999) (6)
- Secondary Prevention of Cardioembolic Stroke: Oldest and Newest Promises (2006) (6)
- Haemorheological Markers in 89 Patients with Stage II Peripheral Vascular Disease (PVD) (1986) (5)
- BRAIN CT SCAN IN ACUTE ISCHEMIC STROKE: EARLY SIGNS AND FUNCTIONAL OUTCOME (2002) (5)
- Idebenone: a guide to its use in Alzheimer’s disease, other age-related cognitive disorders and Friedreich’s ataxia (2010) (5)
- Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ? (2020) (5)
- Dihydroergokryptine vs. placebo in dementia of Alzheimer type: interim results of a randomized multicenter study after a 1-year follow-up. (1996) (5)
- Serum neurofilament light chain as a preclinical marker of neurodegeneration (2019) (5)
- Small-expanded allele spinocerebellar ataxia 17: imaging and phenotypic variability (2021) (5)
- Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection (2021) (5)
- Hot water epilepsy and Mccune–Albright syndrome: A case report (2009) (4)
- 22. Multicentric test-retest reproducibility of human hippocampal volumes with FreeSurfer 6.0: A comparison between standard and longitudinal hippocampal subfields segmentation streams applied to 3D T1, 3D FLAIR and high-resolution 2D T2 neuroimaging (2018) (4)
- CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUT-OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT (2017) (4)
- Seed amplification assays for diagnosing synucleinopathies: the issue of influencing factors. (2021) (4)
- Carotid atherosclerotic disease: role of hypertension and other risk factors. (1993) (4)
- Echotomographic extracranial carotid evaluation in amaurosis fugax, hemispheric TIA and stroke patients. (1986) (4)
- Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker. (2019) (4)
- Headache and ischemic stroke (2002) (4)
- White Matter Hyperintensities Are No Major Confounder for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers (2020) (4)
- Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders (2021) (4)
- Influence of Dementia on Antithrombotic Therapy Prescribed before Stroke in Patients with Atrial Fibrillation (2006) (4)
- CHanGes In endolYsosoMal enzYMe aCtIVItIes In CereBrosPInal (2014) (4)
- Multimodal Use of Computed Tomography in Early Acute Stroke, Part 1 (2006) (4)
- CSF Beta-Amyloid and APOE E4 Related Decline in Episodic Memory over 12 months measured using the CANTAB in individuals with amnestic MCI: Results from the European-ADNI study (2016) (3)
- PHOSPHOLIPID AUTOANTIBODIES: TIME FOR A NEW IMMUNO-ASSAY? (2002) (3)
- New CSF biomarkers on the block (2016) (3)
- Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease (2022) (3)
- Case of posterior cortical atrophy (PCA) evolved to PCA-CBS (2018) (3)
- Dexamethasone suppression test in elderly patients with dementia of Alzheimer type, vascular dementia and stroke: a re-evaluation of its applicability. (1995) (3)
- Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement (2021) (3)
- Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions (2015) (3)
- Teaching NeuroImages: Acute tetraparesis (2009) (3)
- Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers (2020) (3)
- LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY (2017) (3)
- Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia (2017) (3)
- THE INCREMENTAL VALUE OF AMYLOID PET VERSUS CSF BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (INDIA–FBB STUDY) (2018) (3)
- Glycosaminoglycans and Analogs in Neurodegenerative Disorders (2008) (3)
- CSF BETA-AMYLOID- AND APOE Ɛ4-RELATED DECLINE IN EPISODIC MEMORY OVER 12 MONTHS MEASURED USING THE CANTAB IN INDIVIDUALS WITH AMNESTIC MCI: RESULTS FROM THE EUROPEAN ADNI STUDY (2016) (3)
- Lack of Antibodies to HTLV‐II in Patients with Dementia in Italy (1994) (3)
- Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation. (2020) (3)
- The issue of waste disposal in Parkinson's disease pathogenesis (2019) (3)
- An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders (2022) (3)
- Blood pressure and functional aspects of the aging brain. (1989) (3)
- Cholinesterase Inhibitors: From Weapons, to Pesticides, to Cognition Enhancing Drugs (2006) (2)
- CROSS-SECTIONAL BIOMARKER CHARACTERIZATION OF MILD COGNITIVE IMPAIRMENT PATIENTS IN WP5 PHARMACOG/E-ADNI STUDY (2014) (2)
- IN VIVO NEUROCHEMICAL CHARACTERISTICS OF NORMAL AND PATHOLOGICAL AGING OF THE BRAIN : ROLE OF MAGNETIC RESONANCE SPECTROSCOPY (1998) (2)
- THE INCREMENTAL VALUE OF AMYLOID PET VERSUS CSF BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (INDIA–FBB STUDY) (2018) (2)
- Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases (2022) (2)
- HIV-Dementia Scale as a screening tool for the detection of subcortical cognitive deficits: validation of the Italian version (2021) (2)
- CFS Biomarkers in Parkinson’s Disease (2011) (2)
- ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY (2017) (2)
- Clinical and genetic analysis of an Italian family with Machado-Joseph disease (2001) (2)
- Drug-induced Creutzfeldt-Jakob disease-like syndrome: early CSF analysis as useful tool for differential diagnosis (2018) (2)
- Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease? (2010) (2)
- [Whole blood filterability in chronic cerebrovascular disorders: effects of the use of buflomedil hydrochloride]. (1989) (2)
- NfL as Analogue of C-Reactive Protein in Neurologic Diseases (2022) (2)
- Atrial Fibrillation and Stroke (2000) (2)
- Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type (2010) (2)
- PT593. CSF Beta-Amyloid and APOE E4 Related Decline in Episodic Memory over 12 months measured using the CANTAB in individuals with amnestic MCI: Results from the European-ADNI study (2016) (2)
- The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI (2021) (2)
- Gene symbol: NOTCH3. Disease: CADASIL. (2005) (2)
- Characterization of cognitive function with the cantab in individuals with amnestic mild cognitive impairment in relation to hippocampal volume, amyloid, and tau status: Preliminary baseline results from the PharmaCog/european-ADNI study (2015) (2)
- Dihydroergokryptine as long-term treatment of alzheimer type dementia: A multicenter two-year follow-up (1998) (2)
- Impact of post-contrast MRI in the definition of active multiple sclerosis (2022) (2)
- Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease (2022) (1)
- [Effects of buflomedil hydrochloride on the rheological properties of the blood in chronic cerebrovascular diseases]. (1989) (1)
- The effect of oxiracetam treatment on alterations of lipid metabolism in brain areas from spontaneously hypertensive rats. (1989) (1)
- VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION (2018) (1)
- A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias (2022) (1)
- Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson’s and Lewy body diseases (2020) (1)
- ASSOCIATION BETWEEN BRAIN MRI DIFFUSION ALTERATIONS AND CSF BIOMARKERS IN AMNESTIC MCI (2016) (1)
- Progression of symptoms in Parkinson's disease (2020) (1)
- Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease (2022) (1)
- Haemorheological factors in a group of elderly patients with acute mental confusion (2016) (1)
- Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ? (2020) (1)
- Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease (2019) (1)
- The “no evidence of disease activity” (NEDA) concept in MS: Impact of spinal cord MRI (2021) (1)
- Relevance of Aging in Carotid Disease: Results of a Population Survey (1995) (1)
- DIFFERENTIAL EFFECTS OF APOE AND CSF AMYLOID ON MEMORY IMPAIRMENT IN INDIVIDUALS WITH AMNESTIC MCI USING THE CANTAB COGNITIVE BATTERY: RESULTS FROM THE EUROPEAN-ADNI STUDY (2016) (1)
- Cerebrospinal fluid biomarkers and white matter lesions: can we know more? (2010) (1)
- 19th biennial IPEG Meeting (2016) (1)
- Corpus callosum hypoplasia and adult-onset Parkinsonism in DYNC1H1 mutation (2021) (1)
- NOT YET MCI: HOW TO DETECT SUBTLE COGNITIVE IMPAIRMENT? (2016) (1)
- Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use (2022) (1)
- B-Mode Imaging and Histomorphometric Evaluation of Carotid Atherosclerosis (1990) (1)
- Multiple drug interactions induced hyperammonemic encephalopathy in Dravet Syndrome (2021) (1)
- CSF-phospho-tau as a promising marker for discriminating Alzheimer disease from Lewy body dementia (2000) (1)
- Alzheimer's disease versus other degenerative dementias: from biology to treatment (2001) (1)
- CSFBiomarkersandIncipientAlzheimerDisease in Patients With Mild Cognitive Impairment (2009) (1)
- CSF levels of heart fatty acid binding protein in Parkinson's and Alzheimer's disease (2016) (1)
- 234. Susceptibility-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson’s disease (2018) (1)
- Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers. (2019) (1)
- BACK-TRANSLATION OF EEG/ERP MARKERS FROM AMNESTIC MCI PATIENTS TO HEALTHY YOUNG VOLUNTEERS IN THE PHARMACOG PROJECT (2016) (1)
- Abstracts of the IX Congresso Sindem: Italian Association for the study of Dementia linked to the Italian Neurological Society (SIN), March 13-15, 2014, Florence, Italy. (2014) (1)
- Amygdalar nuclei and hippocampal subfields on MRI: Test‐retest reliability of automated segmentation in old and young healthy volunteers (2020) (1)
- Molecular profiling in Parkinsonian syndromes: CSF biomarkers. (2020) (1)
- Proteomic analysis of extracellular vesicles in cerebrospinal fluid of patients with Alzheimer’s disease (2020) (1)
- Clinical correlates of state and trait anxiety in multiple sclerosis. (2022) (1)
- Haemorheological and neuro-psychological patterns in a group of healthy octogenarians (2016) (1)
- International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease (2020) (1)
- Pharmacokinetic Profile and Endocrine Effects of Posatirelin Treatment in Healthy Elderly Subjects (1996) (1)
- Lysosomal enzymes in PD: Further evidence is needed (2014) (1)
- PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study (2022) (1)
- Multi-site hippocampal subfields reproducibility: A european 3T study (2015) (1)
- IMPAIRMENT OF RESTING-STATE FUNCTIONAL CONNECTIVITY IN THE DEFAULT-MODE NETWORK CLOSELY TRACKS CSF BIOMARKERS IN MCI (2016) (1)
- COMBINATION OF CEREBROSPINAL FLUID H-FABP AND CORE ALZHEIMER'S DISEASE BIOMARKERS IMPROVES THE DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATIVE DISORDERS (2016) (1)
- Cortical generation of on-going “Delta” and “Alpha” EEG rhythms in mouse models of Alzheimer’s disease and Alzheimer’s disease patients at prodromic stages (2016) (1)
- The possible role of Optical Coherence Tomography (OCT) and OCT‐Angiography (OCTA) as new non‐invasive biomarkers of prodromal Alzheimer’s disease (2020) (1)
- Aβ42 MEASUREMENT IN FRESH VERSUS STORED CEREBROSPINAL FLUID USING AN AUTOMATED CHEMILUMINESCENT ENZYME IMMUNOASSAY SYSTEM (LUMIPULSE® G600 II) (2018) (0)
- LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes (2023) (0)
- Rare missense variant (R251G) on APOE counterbalances the Alzheimer’s disease risk associated with APOE‐ε4 (2022) (0)
- Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease Patients (2012) (0)
- Multisite hippocampal subfields reproducibility: A european 3T study (2015) (0)
- Educational interventions to improve detection and management of cognitive decline in primary care—An Italian multicenter pragmatic study (2022) (0)
- Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology (2015) (0)
- Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis (2019) (0)
- Aβ/PHOSPHO TAU LOAD IN CSF IS RELATED TO CORTICAL EXCITABILITY AS REVEALED BY CORTICAL EEG BIOMARKERS IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE: THE PHARMACOG PROJECT (2018) (0)
- FingerprintingAlzheimer’s Diseaseby 1H Nuclear Magnetic ResonanceSpectroscopy of Cerebrospinal Fluid (2020) (0)
- Subject Index Vol. 5, 1995 (1995) (0)
- Relationship between haemorheological factors and initial mental deterioration in the elderly. A preliminary study (2016) (0)
- BACK-TRANSLATION OF EEG/ERP MARKERS FROM AMNESTIC MCI PATIENTS TO HEALTHY YOUNG VOLUNTEERS IN THE PHARMACOG PROJECT (2017) (0)
- PT 592 Memantine Monotherapy for Alzheimer ’ s Disease : A Systematic Review and Meta-analysis (2016) (0)
- CEREBROSPINAL FLUID BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONISMS WITH DEMENTIA (2011) (0)
- Aβ42/TAU SPECIES RATIOS ARE ASSOCIATED WITH AMYLOID-PET POSITIVITY IN ALZHEIMER’S DISEASE (2018) (0)
- Carotid atherosclerotic plaques evolution pattern after two year follow up echotomographic analysis (1987) (0)
- A blood test for Alzheimer's disease: a step forward (2021) (0)
- Lysosomal Enzyme in Parkinson's Disease (2017) (0)
- Subject Index Vol. 36, 1996 (1996) (0)
- Serum paraoxonase activity in early phases of acute ischemic stroke. VIII European Stroke Conference (1999) (0)
- Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort (2018) (0)
- ASSOCIATION BETWEEN VOLUME ALTERATIONS AND CSF BIOMARKERS IN AMNESTIC MCI (2016) (0)
- Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
- COGNITIVE COMPOSITE MEASURES IN AMNESTIC MCI BY DIFFERENT AMYLOID/TAU PATHOLOGY (2016) (0)
- Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study (2015) (0)
- Clinical Study Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in (2011) (0)
- Subject Index Vol. 21, 2006 (2006) (0)
- ABNORMALITIES OF ELECTROENCEPHALOGRAPHIC (EEG) MARKERS IN QUIET WAKEFULNESS ARE RELATED TO MOTOR DEFICITS, COGNITIVE SYMPTOMS, AND VISUAL HALLUCINATIONS IN PARKINSON’S DISEASE PATIENTS (2019) (0)
- Contents, Vol 36, 1996 (1990) (0)
- Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline. (2023) (0)
- CSF PROFILE ACCORDING TO A/T/N CLASSIFICATION IN A COHORT OF MCI PATIENTS (2018) (0)
- ASSOCIATION BETWEEN EEG/ERP AND CSF MARKERS IN PRODROMAL ALZHEIMER’S DISEASE IN THE PHARMACOG PROJECT (2016) (0)
- The ‘CSF Alzheimer’s profile’: Easily said, but what do we mean? (2013) (0)
- Gene symbol: Notch3. Disease: CADASIL. (2005) (0)
- Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents (2022) (0)
- Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data (2015) (0)
- Cerebrospinal fluid A/T/(N) profile and mild cognitive impairment in Parkinson's disease (2021) (0)
- Are cortical sources of auditory oddball event-related potentials an early diagnostic marker of Alzheimer’s disease? (2015) (0)
- Patients With Mild Cognitive Impairment CSF Biomarkers and Incipient Alzheimer Disease in Supplementary material (2009) (0)
- [Drinking-water and cardiovascular mortality]. (1982) (0)
- Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context. (2019) (0)
- CORTICAL SOURCES OF RESTING STATE EYES CLOSED EEG RHYTHMS ARE CORRELATED TO CEREBROSPINAL FLUID β AMYLOID IN AMNESTIC MCI SUBJECTS (2014) (0)
- Alfa-D-mannosidases in patients with familial Alzheimer's disease (2000) (0)
- Review for "Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach" (2020) (0)
- Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson’s and Lewy body diseases (2020) (0)
- ITALIAN CONSENSUS RECOMMENDATIONS FOR THE ETIOLOGICAL DIAGNOSIS IN MEMORY CLINICS (2019) (0)
- Interleukin-17 axis in the modulation of cortical and subcortical synaptic plasticity across disease stages in experimental multiple sclerosis (2021) (0)
- Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases (2022) (0)
- Lysosomal enzymes in Parkinson's disease (2017) (0)
- DETECTING EARLY SIGNS OF COGNITIVE IMPAIRMENT IN ASYMPTOMATIC SUBJECTS: AN EXPLORATORY STUDY IN A COHORT OF HEALTHY ELDERLY SUBJECTS (2018) (0)
- BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG® TEST ENABLE STRATIFICATION OF PRE-DEMENTIA ALZHEIMER’S DISEASE (2018) (0)
- 8 Inhibition of COMT reduces cortical motor areas activation in wearing-off Parkinson’s disease patients: An f-MRI study (2012) (0)
- Management of Mild to Moderate (2004) (0)
- ROLE OF THE PAIRED ASSOCIATES LEARNING TASK FROM CANTAB IN THE ASSESSMENT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE AND MCI PATIENTS (2017) (0)
- JAMA Paper supplement (2015) (0)
- Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and clinical neurochemistry. (2019) (0)
- Baseline CSF Aβ, Aβ/T-TAU and Aβ/P-tau distributions to classify pharmacog MCI patients (2016) (0)
- ALPHA-SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER-LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA (2017) (0)
- ID 284 – Abnormal delta cortical sources of resting state eyes closed EEG rhythms correlate with cerebrospinal fluid (CSF) ® amyloid (A®) level in amnesic MCI subjects (2016) (0)
- A CSF biomarker of intrathecal B cells activation correlates with memory impairment in multiple sclerosis (2021) (0)
- Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology (2015) (0)
- Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction (2023) (0)
- Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem) (2022) (0)
- PREDICTING AND MONITORING SHORT-TERM DISEASE PROGRESSION IN A-MCI PATIENTS WITH PRODROMAL AD USING MRI STRUCTURAL BRAIN BIOMARKERS (2018) (0)
- The Italian dementia with lewy bodies study group (DLB-SINDEM): A multicenter survey on the accuracy and the prevalence of DLB diagnosis (2021) (0)
- Blood biomarkers may distinguish among dementia disorders (2022) (0)
- Foreword (2006) (0)
- BASELINE CSF A beta, A beta/T-TAU AND A beta/P-TAU DISTRIBUTIONS TO CLASSIFY PHARMACOG MCI PATIENTS (2016) (0)
- On the Track of Alpha-synuclein in the Body: Skin Biopsies for Diagnosing Synucleinopathies? (2023) (0)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (0)
- 3 CSF Biomarkers in Parkinson ’ s Disease 1 (2012) (0)
- ADFLAG®, A DIAGNOSTIC BLOOD TEST FOR PRE-DEMENTIA STAGES OF ALZHEIMER’S DISEASE (2017) (0)
- No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF (2016) (0)
- BIOMARKERS IN THE EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS (2012) (0)
- Contents, Vol. 34, 1988 (2004) (0)
- Cognitive Function Instrument--Italian Version (2020) (0)
- Cognitive decline in late-onset epilepsy of undefined etiology: A longitudinal cohort study (2021) (0)
- Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies (2018) (0)
- Refractory focal non-convulsive status epilepticus in anti-glur2 encephalitis: Neuro-inflammation and AMPA receptors modulation as target treatment (2021) (0)
- BIOMARKERS OF SHORT TERM DISEASE PROGRESSION IN MILD COGNITIVE IMPAIRMENT PATIENTS WITH AD PATHOLOGY (2016) (0)
- Cross-sectional clinical , neuropsychological , neuroimaging , and neurophysiological characterization of mild cognitive impairment patients in WP 5 PharmaCog / E-ADNI study (2014) (0)
- Are cortical sources of resting state eyes-closed electroencephalographic rhythms an early diagnostic marker of Alzheimer's disease? (2015) (0)
- A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation (2018) (0)
- Do atherosclerotic plaques regress spontaneously in humans (1987) (0)
- Late-onset epilepsy with unknown etiology: Neuropsychological profile, cerebrospinal fluid biomarkers, and quantitative EEG characteristics (2021) (0)
- Atherosclerosis assessment confounders in the Rancho Bernardo study. (2007) (0)
- Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies (2015) (0)
- Longitudinal imaging and biochemical assessments (2016) (0)
- ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY (2017) (0)
- UNDER-REPORTED ON 18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY SCANS OF PATIENTS WITH LEWY BODY DEMENTIA (2018) (0)
- Lysosomal enzyme activities in human brain (2014) (0)
- Contents, Vol. 43, 1997 (1995) (0)
- 1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
- Author and Subject Index (1998) (0)
- Donepezilof its Use in Alzheimer's Disease (2000) (0)
- DIAGNOSTIC PERFORMANCE OF AN AUTOMATED ELISA SYSTEM FOR ALZHEIMER’S DISEASE DETECTION (2016) (0)
- Gene symbol: NOTCH3. Disease: CADASIL. (2005) (0)
- Views New CSF biomarkers on the block (2016) (0)
- Origin of α-mannosidase in CSF (2016) (0)
- Contents Vol. 21, 2006 (2006) (0)
- 457 Proton magnetic resonance spectroscopy in Alzheimer's disease (1996) (0)
- Galantamineic Review of its Use in Alzheimer's Disease (2002) (0)
- Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study (2019) (0)
- Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD (2023) (0)
- Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease (2019) (0)
- Measurement of CSF core AD biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? (2020) (0)
- Lysosomal enzyme activities in postmortem brain tissue of patients with Lewy body diseases (2016) (0)
- CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment (2023) (0)
- PROTEOMIC ANALYSIS OF EXTRACELLULAR VESICLES IN ALZHEIMER’S DISEASE CEREBROSPINAL FLUID (2016) (0)
- Subtle cognitive deficits assessed by means of CANTAB in a cohort of subjects with CSF AD profile (2022) (0)
- Contents Vol 5, 1995 (1995) (0)
- Repeatable Battery for the Assessment of Neuropsychological Status: Italian Normative Data for Older Adults. (2022) (0)
- STRUCTURAL AND DIFFUSION TENSOR IMAGING IN MCI SUBJECTS WITH INTERMEDIATE RISK OF ALZHEIMER’S DISEASE BASED ON CSF PROFILE (2016) (0)
- Carotid disease and stroke the role of arterial hypertension (1991) (0)
- Author and Subject Index (2000) (0)
- Author and Subject Index (2000) (0)
- Subject Index Vol. 43, 1997 (1997) (0)
- The spectrum of NOTCH3 mutation and phonotype variability in fourteen Italian families with CADASIL. (2003) (0)
- CROSS-SECTIONAL STUDIES OF PLASMA PROTEOMIC BIOMARKERS RELATING TO PET AMYLOID AND CSF AMYLOID AND TAU (2016) (0)
- Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data (2015) (0)
- CSF AD‐like profile in SCD, pre‐MCI and MCI subjects: Application of the A/T/N classification model in a retrospective cohort from a memory clinic (2020) (0)
- FRONTAL CORTICAL SOURCES OF AUDITORY ODDBALL EVENT-RELATED POTENTIALS ARE RELATED TO CEREBROSPINAL FLUID β AMYLOID IN AMNESTIC MCI SUBJECTS (2014) (0)
- STRUCTURAL AND DIFFUSION TENSOR IMAGING IN MCI SUBJECTS WITH INTERMEDIATE RISK OF ALZHEIMER’S DISEASE BASED ON CSF PROFILE (2016) (0)
- Role of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease (2011) (0)
- Cerebrospinal fluid in Alzheimer's: A precious tool (2016) (0)
- Which pre‐analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test (2020) (0)
- 99mTc-HMPAO SPECT in Borderline Conditions Related to the Aging Brain (1999) (0)
- On the Track of α-Synuclein in the Body (2023) (0)
- Chronic cerebrovascular disorders: hemorheological and psychobehavioral aspects. (1986) (0)
- Progress in CSF biomarker discovery for mild cognitive impairment and Alzheimer's Disease by label-free quantitative proteomics (2011) (0)
- ASSOCIATION BETWEEN VOLUMES ALTERATIONS AND CSF BIOMARKERS IN AMNESTIC MCI (2016) (0)
- Welcome to the New Open Access NeuroSci (2020) (0)
- Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation (2022) (0)
- ROLE OF THE INFLAMMASOME COMPLEX IN AD-RELATED HIPPOCAMPAL NEURODEGENERATION IN MCI PATIENTS WITH AD PATHOLOGY (2018) (0)
- The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients (2019) (0)
- Preface (2000) (0)
- Stroke: Treatment, Prevention and Rehabilitation: Perugia 1st International Stroke Meeting, Perugia, November 1999 (2000) (0)
- Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays (2023) (0)
- ID 286 – Auditory oddball event-related potentials cortical sources are related to cerebrospinal fluid (CSF)® amyloid (A®) level in amnesic MCI subjects (2016) (0)
- Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease (2017) (0)
- A panel of novel astrocytic and synaptic biomarkers in serum and CSF for the differential diagnosis of frontotemporal dementia (2021) (0)
- Origin of lysosomal enzymes in human cerebrospinal fluid (2015) (0)
- Poor Reactivity of Posterior Electroencephalographic Alpha Rhythms During the Eyes Open Condition in Patients with Dementia Due to Parkinson’s Disease (2022) (0)
- PHOSPHO-TAU (181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies (2006) (0)
- Dementias and cognitive disorders: New insights and approaches (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Lucilla Parnetti?
Lucilla Parnetti is affiliated with the following schools:
